Co-Infection Associated with SARS-CoV-2 and Their Management

References

• ParasherA. COVID-19: current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med. J.97, 312–320 (2021).
   PubMed Web of Science ®Google Scholar
• HassanSS , GhoshS , AttrishDet al.Possible transmission flow of SARS-CoV-2 based on ACE2 features. Mol.25 (2020).
   Web of Science ®Google Scholar
• TosepuR , GunawanJ , EffendyDSet al.Correlation between weather and COVID-19 pandemic in Jakarta, Indonesia. Sci. Total Environ.725, 138436 (2020).
   PubMed Web of Science ®Google Scholar
• HuB. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol.19, 141–154 (2019).
   Web of Science ®Google Scholar
• MachhiJ , HerskovitzJ , SenanAMet al.The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. (2020).
   Google Scholar
• HoffmannM , Kleine-WeberH , SchroederSet al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell181, 271–280.e8 (2020).
   PubMed Web of Science ®Google Scholar
• Bar-onYM , FlamholzAVI , PhillipsROBet al.SARS-CoV-2 (COVID-19) by the numbers. 2, 1–15 (2020).
   Google Scholar
• XieSHUYUN , OuJIANMING. Infectivity of severe acute respiratory syndrome during. 510, 502–510 (2009).
   Google Scholar
• WeiWE , LiZ , ChiewCJet al.Presymptomatic transmission of SARS-CoV-2 – Singapore,. 69, 411–415 (2020).
   Google Scholar
• SamavatiL , UhalBD. ACE2, much more than just a receptor for SARS-COV-2. Front. Cell. Infect. Microbiol.317 (2020). https://doi.org/10.3389/fcimb.2020.00317
   PubMed Web of Science ®Google Scholar
• MondalS , QuintiliAL , KaramchandaniKet al.Thromboembolic disease in COVID-19 patients: a brief narrative review. J Intensive Care8, 1–10 (2020).
   PubMed Web of Science ®Google Scholar
• LiX , MaX. Acute respiratory failure in COVID-19: is it “typical” ARDS?Crit Care24, 198 (2020). https://doi.org/10.1186/s13054-020-02911-9
   PubMed Web of Science ®Google Scholar
• ChavdaVP , VoraLK , PandyaAKet al.Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov. Today26, 2619–2636 (2021). www.sciencedirect.com/science/article/pii/S1359644621003317
   PubMed Web of Science ®Google Scholar
• ChavdaVP , VoraLK , ViholDR. COVAX-19® Vaccine: completely blocks virus transmission to non-immune individuals. Clin. Complement Med. Pharmacol.1, 100004 (2021). www.sciencedirect.com/science/article/pii/S2772371221000048
   Google Scholar
• ChavdaVP , PandyaR , ApostolopoulosV. DNA vaccines for SARS-CoV-2: towards third generation vaccination era. Expert Rev Vaccines20, 1–21 (2021).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , FeehanJ , ApostolopoulosV. A veterinary vaccine for SARS-CoV-2: the first COVID-19 vaccine for animals. Vaccines9, 631 (2021).
   PubMed Web of Science ®Google Scholar
• NalbandianA , SehgalK , GuptaAet al.Post-acute COVID-19 syndrome. Nat. Med.27, 601–615 (2021).
   PubMed Web of Science ®Google Scholar
• Wikipedia. Variants of SARS-CoV-2. 2021.
   Google Scholar
• HarveyWT , CarabelliAM , JacksonBet al.SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol., 614 (2021).
   Web of Science ®Google Scholar
• ReesH , RoperoAM , ScBet al.Special report SARS-CoV-2 variants and vaccines. 1–8 (2021).
   Google Scholar
• CDC. SARS-CoV-2 variant classifications and definitions (2021). www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
   Google Scholar
• SinghR , KangA , LuoXet al.COVID-19: current knowledge in clinical features, immunological responses, and vaccine development. FASEB J.35, 1–23 (2021).
   Web of Science ®Google Scholar
• EmaryKRW , GolubchikT , AleyPKet al.Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet (London, England)397, 1351–1362 (2021).
   PubMed Web of Science ®Google Scholar
• KhatriA , ChangK , BerlinrutIet al.Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 Resource Centre is Hosted on Elsevier Connect, the Company's Public News and Information52 (2020).
   Google Scholar
• ChavdaVP , PatelAB , VaghasiyaDD. SARS-CoV-2 variants and vulnerability at the global level. J. Med. Virol.94, 2986–3005 (2022).
   PubMed Web of Science ®Google Scholar
• HuangZ , ChavdaVP , VoraLKet al.2-Deoxy-D-Glucose and its derivatives for the COVID-19 treatment: an update. Front Pharmacol.13, 899633 (2022).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , GajjarN , ShahNet al.Darunavir ethanolate: repurposing an anti-HIV drug in COVID-19 treatment. Eur. J. Med. Chem. Reports3, 100013 (2021).
   PubMedGoogle Scholar
• MohammadiM , ShayestehpourM , MirzaeiH. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Brazilian J Infect Dis an Off Publ Brazilian Soc Infect Dis.25, 101606 (2021).
   PubMed Web of Science ®Google Scholar
• HadjHassine I. Covid-19 vaccines and variants of concern: a review. Rev. Med. Virol.32, e2313 (2022).
   PubMed Web of Science ®Google Scholar
• CDC. About variants of the virus that causes COVID-19. CDC Gov. (2021).
   Google Scholar
• WHO. The effects of virus variants on COVID-19 vaccines. 1–5 (2021). www.whoint
   Google Scholar
• KhandiaR , SinghalS , AlqahtaniTet al.Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ. Res.209, 112816 (2022).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , PatelAB , ViholDet al.Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update. Clin. Complement Med. Pharmacol.100021 (2022). www.sciencedirect.com/science/article/pii/S2772371222000031
   PubMedGoogle Scholar
• ChavdaVP , HanumaKumar Ghali EN , YallapuMMet al.Therapeutics to tackle Omicron outbreak. Immunotherapy (2022
   Web of Science ®Google Scholar
• VivekP. Chavda. Omicron variant (B.1.1.529) of SARS-CoV-2: threat for the elderly? (2020).
   Google Scholar
• RahimiF , TalebiBezmin Abadi A. Hybrid SARS-CoV-2 variants. Int. J. Surg.102, 106656 (2022).
   PubMed Web of Science ®Google Scholar
• ChakrabortyC , BhattacharyaM , SharmaARet al.Recombinant SARS-CoV-2 variants XD, XE, and XF: the emergence of recombinant variants requires an urgent call for research - Correspondence. Int. J. Surg., 106670 (2022).
   PubMed Web of Science ®Google Scholar
• JalkanenP , KolehmainenP , HäkkinenHKet al.COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun.12, 1–11 (2021).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , SoniS , PrajapatiRet al.Reply to the letter ‘Effectiveness of COVID-19 vaccines against Omicron variant.’. Immunotherapy (2022
   Web of Science ®Google Scholar
• WuK , WernerAP , MolivaJIet al.mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. BioRxiv Prepr. Serv. Biol.55, 355–365 (2021).
   Google Scholar
• JiangL , TangK , LevinMet al.COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis.20, e276–e288 (2020).
   PubMed Web of Science ®Google Scholar
• ThiagarajanK. COVID-19: india is at centre of global vaccine manufacturing, but opacity threatens public trust. BMJ372, n196 (2021).
   PubMedGoogle Scholar
• JeffCraven. COVID-19 vaccine tracker. Regul. Focus. (2021). www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker
   Google Scholar
• WHO. Vaccine information.
   Google Scholar
• AleemA , AkbarSamad AB , SlenkerAK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). Treasure Island (FL)54524–540 (2022).
   Google Scholar
• ChavdaVP , ApostolopoulosV. Is booster dose strategy sufficient for omicron variant of SARS-CoV-2?Vaccines10, 367 (2022).
   PubMed Web of Science ®Google Scholar
• SinghDD , ParveenA , YadavDK. Corrigendum: SARS-CoV-2: emergence of new variants and effectiveness of vaccines. Front Cell Infect Microbiol.12, 885482 (2022).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , PandyaR , ApostolopoulosV. DNA vaccines for SARS-CoV-2: toward third-generation vaccination era. Expert Rev Vaccines.20, 1549–1560 (2021).
   PubMed Web of Science ®Google Scholar
• DunkleLM , KotloffKL , GayCLet al.Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med.386, 531–543 (2022).
   PubMed Web of Science ®Google Scholar
• Lopes-PachecoM , SilvaPL , CruzFF. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies. 12, 1–23 (2021).
   Google Scholar
• EsquivelA , BusseWW , CalatroniAet al.Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am. J. Respir. Crit. Care Med.196, 985–992 (2017).
   PubMed Web of Science ®Google Scholar
• SteutenK , KimH , WidenJCet al.Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors. 2020, 1–32
   Google Scholar
• SummaryE. Therapeutic Management of Patients With COVID-19. 2021, 75–88
   Google Scholar
• NovemberO , AuthorizationEU , DecemberOet al.The COVID-19 Treatment Guidelines panel's statement on baricitinib for the treatment of adults with COVID-19. 2021, 6–7
   Google Scholar
• BasuD , ChavdaVP , MehtaAA. Therapeutics for COVID-19 and post COVID-19 complications: an update. Curr Res Pharmacol Drug Discov100086 (2022). www.sciencedirect.com/science/article/pii/S2590257122000062
   PubMedGoogle Scholar
• CovidT , PanelTG , CovidAW. What's new in the guidelines. 2019, 4–5 (2021).
   Google Scholar
• ChavdaVP , KapadiaC , SoniSet al.A global picture: therapeutic perspectives for COVID-19. Immunotherapy10.2217/imt-2021–0168 (2022). https://doi.org/10.2217/imt-2021-0168
   Web of Science ®Google Scholar
• Eli Lilly and Company. Fact sheet for healthcare providers Emergency Use Authorization (EUA) for baricitinib. US Food Drug Adm.1–29 (2021).
   Google Scholar
• ControlD. What clinicians need to know about the new oral antiviral medications for COVID-19. (2022).
   Google Scholar
• UludagG , OnghansengN , TranANTet al.Current concepts in the diagnosis and management of antiphospholipid syndrome and ocular manifestations. J. Ophthalmic Inflamm. Infect.11 (2021).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , PrajapatiR , LathigaraDet al.Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther.1–18 (2022).
   Web of Science ®Google Scholar
• MokhtariT , HassaniF , GhaffariNet al.COVID-19 and multiorgan failure: a narrative review on potential mechanisms. J. Mol. Histol.51, 613–628 (2020).
   PubMed Web of Science ®Google Scholar
• DongM , ZhangJ , MaXet al.Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 Resource Centre is Hosted on Elsevier Connect, the Company's Public News and Information52 (2020).
   Google Scholar
• MundellBE , PreidtR. Many show long-term organ damage after COVID. (2021)
   Google Scholar
• SinghAK , SinghR , JoshiSRet al.Mucormycosis in COVID-19: a Systematic Review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev (2021
   Web of Science ®Google Scholar
• MeghnaSen. Black Fungus: these 2 states account for nearly 42% of India's 28,252 mucormycosis cases. Livemint.8 (2021).
   Google Scholar
• ThackerD. Multisystem Inflammatory Syndrome in Children (MIS-C): Delaware J Public Heal. 6, 36–39 (2020).
   Google Scholar
• OrCaspi , MichaelJ , SmartRBN. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. Ann. Oncol., 19–21 (2020).
   Google Scholar
• ShawahnaR , JaradatNA. Ethnopharmacological survey of medicinal plants used by patients with psoriasis in the West Bank of Palestine. BMC Complement Altern Med.17, 1–9 (2017).
   PubMed Web of Science ®Google Scholar
• GargD , MuthuV , SehgalISet al.Coronavirus Disease (COVID-19) associated mucormycosis (CAM): Case Report and Systematic Review of literature. Mycopathologia186, 289–298 (2021).
   PubMed Web of Science ®Google Scholar
• WidysantoA , WahyuniTD , SimanjuntakLHet al.Happy hypoxia in critical COVID-19 patient: a case report in Tangerang, Indonesia. Physiol Rep.8, 1–5 (2020).
   Web of Science ®Google Scholar
• JounieauxV , RodensteinDO , MahjoubY. On happy hypoxia and on sadly ignored “acute vascular distress syndrome” in patients with COVID-19. Am. J. Respir. Crit. Care Med.202, 1598–1599 (2020).
   PubMed Web of Science ®Google Scholar
• HussainS , RiadA , SinghAet al.Global prevalence of COVID-19-associated mucormycosis (CAM): living Systematic Review and Meta-Analysis. J. Fungi (Basel, Switzerland)7 (2021).
   Google Scholar
• MehandruS , MeradM. Pathological sequelae of long-haul COVID. Nat. Immunol.23, 194–202 (2022).
   PubMed Web of Science ®Google Scholar
• TeixeiraTA , BernardesFS , OliveiraYCet al.SARS-CoV-2 and multi-organ damage – what men's health specialists should know about the COVID-19 pathophysiology. Int. Braz. J. Urol.47, 637–646 (2021).
   PubMed Web of Science ®Google Scholar
• OjoAS , BalogunSA , WilliamsOTet al.Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Kuwano K, editor. Pulm. Med.2020, 6175964 (2020). https://doi.org/10.1155/2020/6175964
   PubMed Web of Science ®Google Scholar
• SafiabadiTali SH , LeBlancJJ , SadiqZet al.Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection. Clin. Microbiol. Rev.34, 1–63 (2021).
   Web of Science ®Google Scholar
• LiuJ , ZhengX , TongQet al.Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J. Med. Virol.92, 491–494 (2020). https://doi.org/10.1002/jmv.25709
   PubMed Web of Science ®Google Scholar
• ValdebenitoS , BessisS , AnnaneDet al.COVID-19 lung pathogenesis in SARS-CoV-2 autopsy cases. Front Immunol.12, 735922 (2021).
   PubMed Web of Science ®Google Scholar
• WonT , WoodMK , HughesDMet al.Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs. EBioMedicine.75, 103812 (2022).
   PubMed Web of Science ®Google Scholar
• AliRMM , GhonimyMBI. Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egypt J. Radiol. Nucl. Med.52, 101 (2021). https://doi.org/10.1186/s43055-021-00484-3
   Google Scholar
• Basu-RayI , AlmaddahNk , AdeboyeAet al.Cardiac manifestations of coronavirus (COVID-19) [updated 2021 May 19]. In: StatPearls.StatPearls Publishing, FL, USA (2021). www.ncbi.nlm.nih.gov/books/NBK556152/
   Google Scholar
• SmadjaDM , MentzerSJ , FontenayMet al.COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects. Angiogenesis.Springer, The Netherlands (2021).
   Google Scholar
• ZieglerCGK , MiaoVN , OwingsAHet al.Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell184, 4713–4733.e22 (2021).
   PubMed Web of Science ®Google Scholar
• HalawaS , PullamsettiSS , BanghamCRMet al.Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. Nat Rev Cardiol.19, 314–331 (2022).
   PubMed Web of Science ®Google Scholar
• XieY , XuE , BoweBet al.Long-term cardiovascular outcomes of COVID-19. Nat. Med.28, 583–590 (2022). https://doi.org/10.1038/s41591-022-01689-3
   PubMed Web of Science ®Google Scholar
• DongM , ZhangJ , MaXet al.ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed. Pharmacother.131, 110678 (2020). https://pubmed.ncbi.nlm.nih.gov/32861070
   PubMed Web of Science ®Google Scholar
• DekoskyST , KochanekPM , ValadkaABet al.Blood biomarkers for detection of brain injury in COVID-19 patients. J. Neurotrauma38, 1–43 (2021).
   PubMed Web of Science ®Google Scholar
• SulzerD , AntoniniA , LetaVet al.COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside. npj Park. Dis.6, 18 (2020). https://doi.org/10.1038/s41531-020-00123-0
   PubMed Web of Science ®Google Scholar
• BhaskarS , BradleyS , Israeli-KornSet al.Chronic neurology in COVID-19 era: clinical considerations and recommendations from the REPROGRAM consortium [Internet]. Front. Neurol.664 (2020). https://doi.org/10.3389/fneur.2020.00664
   PubMed Web of Science ®Google Scholar
• PtacekR , PtackovaH , MartinAet al.Psychiatric manifestations of COVID-19 and their social significance. Med. Sci. Monit.26, 1–3 (2020).
   Web of Science ®Google Scholar
• RogersJP , ChesneyE , OliverDet al.Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a Systematic Review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry7, 611–627 (2020).
   PubMed Web of Science ®Google Scholar
• D'ArcyRCN , SandhuJK , MarshallSet al.Mitigating long-term COVID-19 consequences on brain health. Front Neurol.12, 630986 (2021).
   PubMed Web of Science ®Google Scholar
• SabaghianT , KharazmiAB , AnsariAet al.COVID-19 and acute kidney injury: a Systematic Review [Internet]. Front. Med. (2022).
   Google Scholar
• WangM , XiongH , ChenHet al.Renal injury by SARS-CoV-2 infection: a Systematic Review. Kidney Dis7, 100–110 (2021). https://doi.org/10.1159/000512683
   Google Scholar
• LegrandM , BellS , ForniLet al.Pathophysiology of COVID-19-associated acute kidney injury. Nat. Rev.Nephrol. (2021).
   PubMed Web of Science ®Google Scholar
• AhmadianE , HosseiniyanKhatibi SM , RaziSoofiyani Set al.COVID-19 and kidney injury: pathophysiology and molecular mechanisms. Rev. Med. Virol.31, 1–13 (2021).
   Web of Science ®Google Scholar
• MarjotT , WebbGJ , BarrittASet al.COVID-19 and liver disease: mechanistic and clinical perspectives. Nat. Rev. Gastroenterol. Hepatol.18, 348–364 (2021).
   PubMed Web of Science ®Google Scholar
• AliN. Relationship between COVID-19 infection and liver injury: a review of recent data. Front Med.7, 458 (2020).
   Web of Science ®Google Scholar
• ThakurV , RathoRK , KumarPet al.Multi-organ involvement in COVID-19: beyond pulmonary manifestations. J. Clin. Med.10, 446 (2021).
   PubMed Web of Science ®Google Scholar
• VitielloA , LaPorta R , D'AiutoVet al.The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced. Egypt Liver J.11, 11 (2021). https://doi.org/10.1186/s43066-021-00082-y
   PubMedGoogle Scholar
• PericoL , BenigniA , CasiraghiFet al.Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat. Rev. Nephrol.17, 46–64 (2021).
   PubMed Web of Science ®Google Scholar
• SunB , TangN , PelusoMJet al.Characterization and Biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells10, 386 (2021).
   PubMed Web of Science ®Google Scholar
• SharmaS , GroverM , BhargavaSet al.Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J. Laryngol. Otol.1–6 (2021).
   Web of Science ®Google Scholar
• VinayagamS , SattuK. SARS-CoV-2 and coagulation disorders in different organs. Life Sci.260, 118431 (2020).
   PubMed Web of Science ®Google Scholar
• KallapurAS , YenEY , SinghRR. Vascular thrombosis in COVID-19: a potential association with antiphospholipid antibodies: a rapid Systematic Review of pathology and laboratory medicine, UCLA, Los Angeles, CA. of Medicine, University of California at Los Angeles (UCLA) David Geff. 1670 (2020).
   Google Scholar
• AndradeBS , SiqueiraS , deAssis Soares WRet al.Long-covid and post-covid health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses2021, 13 (2021).
   Google Scholar
• OrsiniA , CorsiM , SantangeloAet al.Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. Neurol Sci.41, 2353–2366 (2020).
   PubMed Web of Science ®Google Scholar
• SyamAF. Gastrointestinal disorders in COVID-19 patients: a great imitator. Med. J. Indones, 1–4 (2021).
   Web of Science ®Google Scholar
• GuoM , TaoW , FlavellRAet al.Potential intestinal infection and faecal–oral transmission of SARS-CoV-2. Nat. Rev. Gastroenterol. Hepatol.18, 269–283 (2021). https://doi.org/10.1038/s41575-021-00416-6
   PubMed Web of Science ®Google Scholar
• SavarinoEV , IovinoP , SantonicolaAet al.Clinical and psychological impact of COVID-19 infection in adult patients with eosinophilic gastrointestinal disorders during the SARS-CoV-2 outbreak. J. Clin. Med.9, 2011 (2020).
   PubMed Web of Science ®Google Scholar
• Chih-ChengLai a , Tzu-PingShih b , Wen-ChienKo c , Hung-JenTang d P-RH. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 Resource Centre is Hosted on Elsevier Connect, the Company's Public News and Information52 (2020).
   Google Scholar
• GottliebM , LongB. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information. Am. J. Emerg.38, 1715–1721 (2020).
   PubMed Web of Science ®Google Scholar
• RabaanAA , Al-AhmedSH , MuhammadJet al.Role of inflammatory cytokines in COVID-19 patients: a review on molecular mechanisms, immune functions, immunopathology and immunomodulatory drugs to counter cytokine storm. Vaccines9 (2021).
   Web of Science ®Google Scholar
• SongC-Y , XuJ , HeJ-Qet al.Immune dysfunction following COVID-19, especially in severe patients. Sci. Rep.10, 15838 (2020).
   PubMed Web of Science ®Google Scholar
• WuY , HuangX , SunJet al.Clinical characteristics and immune injury mechanisms in 71 patients with COVID-19. mSphere5 (2020).
   Web of Science ®Google Scholar
• DhavalShah , Vivek ChavdaHT. Nasal medication conveyance framework: an approach for brain delivery from essential to cutting edge. Res. Rev. J. Med.6, 14–27 (2016).
   Google Scholar
• EsmaeilzadehA , JafariD , TahmasebiSet al.Immune-based therapy for COVID-19. Adv. Exp. Med. Biol.1318, 449–468 (2021).
   PubMed Web of Science ®Google Scholar
• EsmaeilzadehA , RostamiS , YeganehPMet al.Recent advances in antibody-based immunotherapy strategies for COVID-19. J. Cell Biochem.122, 1389–1412 (2021).
   PubMed Web of Science ®Google Scholar
• HashemiB , AkramF-A , AmirazadHet al.Emerging importance of nanotechnology-based approaches to control the COVID-19 pandemic; focus on nanomedicine iterance in diagnosis and treatment of COVID-19 patients. J. Drug Deliv. Sci. Technol.67, 102967 (2022).
   PubMed Web of Science ®Google Scholar
• PrakashH , ChakrabartiA. Global epidemiology of mucormycosis. J. Fungi (Basel, Switzerland)5, 26 (2019). https://pubmed.ncbi.nlm.nih.gov/30901907
   PubMedGoogle Scholar
• SaldanhaM , ReddyR , VincentMJ. Title of the article: paranasal mucormycosis in COVID-19 patient. Indian J. Otolaryngol. Head Neck Surg., 1–4 (2021).
   PubMed Web of Science ®Google Scholar
• AmanatiA , BarzegarH , PouladfarGet al.Orbital mucormycosis in immunocompetent children; review of risk factors, diagnosis, and treatment approach. BMC Infect. Dis.20, 770 (2020).
   PubMed Web of Science ®Google Scholar
• RevannavarSM , SSP , SamagaLet al.COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?BMJ Case Rep.14, e241663 (2021). https://pubmed.ncbi.nlm.nih.gov/33906877
   PubMedGoogle Scholar
• ChavdaVP , ApostolopoulosV. Mucormycosis – An opportunistic infection in the aged immunocompromised individual: a reason for concern in COVID-19. Maturitas58, 58–61 (2021). www.sciencedirect.com/science/article/pii/S0378512221001365
   Google Scholar
• AhmadikiaK , HashemiSJ , KhodavaisySet al.The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses (2021). https://pubmed.ncbi.nlm.nih.gov/33590551
   Web of Science ®Google Scholar
• IbrahimAS , SpellbergB , WalshTJet al.Pathogenesis of mucormycosis. Clin. Infect. Dis.54, 1–7 (2012).
   PubMed Web of Science ®Google Scholar
• AlekseyevK , DidenkoL , ChaudhryB. Rhinocerebral mucormycosis and COVID-19 pneumonia. J. Med. Cases.12, 85–89 (2021).
   PubMedGoogle Scholar
• PrakashH , ChakrabartiA. Epidemiology of mucormycosis in India. Microorganisms9, 523 (2021).
   PubMed Web of Science ®Google Scholar
• SkiadaA , PavleasI , Drogari-ApiranthitouM. Epidemiology and diagnosis of mucormycosis: an update. J. Fungi (Basel, Switzerland)6, 265 (2020). https://pubmed.ncbi.nlm.nih.gov/33147877
   PubMedGoogle Scholar
• Waizel-HaiatS , Guerrero-PazJA , Sanchez-HurtadoLet al.A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus13, e13163–e13163 (2021).
   PubMed Web of Science ®Google Scholar
• PilmisB , AlanioA , LortholaryOet al.Recent advances in the understanding and management of mucormycosis. F1000Research.7, 1–8 (2018).
   Google Scholar
• SenM , LahaneS , LahaneTPet al.Mucor in a viral land: a tale of two pathogens. Indian J. Ophthalmol.69, 244–252 (2021).
   PubMed Web of Science ®Google Scholar
• PaseroD , SannaS , LiperiCet al.A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection, 1–6 (2020).
   Web of Science ®Google Scholar
• KhatriA , ChangK-M , BerlinrutIet al.Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient – case report and review of literature. J. Mycol. Med.31, 101125 (2021).
   PubMed Web of Science ®Google Scholar
• ChikleyA , Ben-AmiR , KontoyiannisDP. Mucormycosis of the central nervous system. J. Fungi (Basel, Switzerland)5, 59 (2019).
   PubMedGoogle Scholar
• DevanaSK , BoraGS , MavuduruRSet al.Successful management of renal mucormycosis with antifungal therapy and drainage. Indian J. Urol.32, 154–155 (2016).
   PubMedGoogle Scholar
• MehtaS , PandeyA. Rhino-orbital mucormycosis associated with COVID-19. Cureuse10726 (2020).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , HossainMK , BeladiyaJet al.Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena. Biologics.1, 337–356 (2021).
   Google Scholar
• SenM , HonavarSG , SharmaNet al.COVID-19 and eye: a review of ophthalmic manifestations of COVID-19. Indian J. Ophthalmol.69, 488–509 (2021).
   PubMed Web of Science ®Google Scholar
• JohnTM , JacobCN , KontoyiannisDP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J. Fungi (Basel, Switzerland)7, 298 (2021).
   PubMedGoogle Scholar
• GhaziabadI. COVID: india's ‘white fungus’ infections raise new health concerns COVID-19 Special: ‘Black fungus’ infections rise in India COVID: An unfolding health crisis in rural India. 1–3 (2021).
   Google Scholar
• SterlingB. White Fungus. Beyond30, 1–2 (2020)
   Google Scholar
• GaoD , DuL , YangJet al.A critical review of the application of white rot fungus to environmental pollution control. Crit. Rev. Biotechnol.30, 70–77 (2010).
   PubMed Web of Science ®Google Scholar
• NowS. Black fungus, white fungus and yellow fungus: busting some common myths related to the dangerous fungal infections developed post-COVID recovery. 1–5 (2021).
   Google Scholar
• LoadedTHEF. Explained: What Are Black, White. 1–10 (2021).
   Google Scholar
• AhmedN , MahmoodMS , UllahMAet al.COVID-19-associated candidiasis: possible patho-mechanism, predisposing factors, and prevention strategies. Curr Microbiol.79, 127 (2022).
   PubMed Web of Science ®Google Scholar
• Segrelles-CalvoG , deS Araújo GR , Llopis-PastorEet al.Candida spp. co-infection in COVID-19 patients with severe pneumonia: prevalence study and associated risk factors. Respir. Med.188, 106619 (2021).
   PubMed Web of Science ®Google Scholar
• HuzarT. COVID-19: how do we explain “happy” hypoxia?Med. News Today1–6 (2020).
   Google Scholar
• WhatS , IsE , HypoxiaH. Happy hypoxia: decoding the mystery COVID-19 patients. 4–7 (2021).
   Google Scholar
• A-zH. Silent hypoxia or happy hypoxia in COVID-19 patients what is silent or happy hypoxia? What are the symptoms of silent or happy hypoxia to watch for? What causes silent or happy hypoxia in COVID-19 patients?. How to Identify Silent or Happy Hypoxia in Pa.1–3 (2021).
   Google Scholar
• DhontS , DeromE , Van BraeckelEet al.Conceptions of the pathophysiology of happy hypoxemia in COVID-19. Respir. Res.22, 21–23 (2021).
   PubMed Web of Science ®Google Scholar
• BrouquiP , AmraneS , MillionMet al.Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 Resource Centre is Hosted on Elsevier Connect, the Company's Public News and Information52 (2020).
   Google Scholar
• NegriEM , PilotoBM , MorinagaLKet al.Heparin therapy improving hypoxia in COVID-19 patients – a case series [Internet]. Front. Physiol. (2020). https://doi.org/10.3389/fphys.2020.573044
   Web of Science ®Google Scholar
• DchSG , ChopraN , SinghAet al.Unusual clinical manifestations and outcome of multisystem inflammatory syndrome in children (MIS-C) in a tertiary care hospital of North India. 1–9 (2021).
   Google Scholar
• McmurrayJC , MayJW , CunninghamMW. Multisystem inflammatory syndrome in children (MIS-C), a post-viral myocarditis and systemic vasculitis – a critical review of its pathogenesis and treatment. 8, 11–23 (2020).
   Google Scholar
• RostadBS , ShahJH , RostadCAet al.Chest radiograph features of multisystem inflammatory syndrome in children (MIS-C) compared to pediatric COVID-19. (2021).
   Google Scholar
• PatelM , MouskasK , SimonsNet al.Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C). (2020).
   Google Scholar
• RamaswamyRA , BrodskyNN , SumidaTSet al.Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity54, 1083–1095.e7 (2020).
   Web of Science ®Google Scholar
• ChavdaVP , ViholD , MehtaBet al.Phytochemical-loaded liposomes for anticancer therapy: an updated review. Nanomedicine (2022
   PubMed Web of Science ®Google Scholar
• VellaLA , ImmunolS , VellaLAet al.Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. 7570, 1–18 (2021).
   Google Scholar
• ConsiglioCR , NicolaC , SardhF , PouCet al.The immunology of multisystem inflammatory syndrome in children with COVID-19. 183, 4968–981 (2020).
   Google Scholar
• ElHasbani G , TaherAT , JawadAet al.COVID-19, antiphospholipid antibodies, and catastrophic antiphospholipid syndrome: a possible association?Clin. Med. Insights Arthritis Musculoskelet Disord.13 (2020).
   Web of Science ®Google Scholar
• BustamanteJG , GoyalA ; SinghalM. StatPearls – NCBI Bookshelf Antiphospholipid syndrome. 1200–1500 (2022).
   Google Scholar
• CavalliE , BramantiA , CiurleoRet al.Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: diagnostic and therapeutic perspectives (Review). 903–912 (2020).
   Google Scholar
• ArnouxD , BoutièreB , SanmarcoM. [Antiphospholipid antibodies: clinical significance and biological diagnosis]. Ann Biol Clin (Paris)58, 557–574 (2000).
   PubMed Web of Science ®Google Scholar
• OliveiraDC , CorreiaA , OliveiraC. The issue of the antiphospholipid antibody syndrome. J. Clin. Med. Res.12, 286–292 (2020).
   PubMedGoogle Scholar
• ChavdaVP , ApostolopoulosV. Global impact of delta plus variant and vaccination. Expert Rev. Vaccines (2022
   Web of Science ®Google Scholar
• SerranoM , EspinosaG , SerranoA , CerverabR. Antiphospholipid syndrome and COVID-19 – what you should know. Elsevier Public Health Emergency Collection
   Google Scholar
• PanthamP , AbrahamsVM , ChamleyLW. The role of anti-phospholipid antibodies in autoimmune reproductive failure. Reproduction.151, R79–90 (2016).
   PubMed Web of Science ®Google Scholar
• ButtN , AhmadH , KhalidNet al.Cardiovascular manifestations of COVID-19. Arch Clin Biomed Res.04, 1–21 (2020).
   Google Scholar
• HughesS , TroiseO , DonaldsonHet al.Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin. Microbiol. Infect.26, 1395–1399 (2020).
   PubMed Web of Science ®Google Scholar
• RedwanEM , AlghamdiMF , El-AzizTMAet al.The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. Autoimmun Rev20, 102909 (2021). www.sciencedirect.com/science/article/pii/S1568997221001841
   PubMed Web of Science ®Google Scholar
• IndexCC. Presence of antiphospholipid antibodies in COVID-19: a case series study. 80, 19–20 (2021).
   Google Scholar
• ElrashdyF , TambuwalaMM , HassanSSet al.Autoimmunity roots of the thrombotic events after COVID-19 vaccination. Autoimmun. Rev.20, 102941 (2021). www.sciencedirect.com/science/article/pii/S1568997221002160
   PubMed Web of Science ®Google Scholar
• BowlesL , PlattonS , YarteyNet al.Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N. Engl. J. Med.383, 288–290 (2020).
   PubMed Web of Science ®Google Scholar
• ElHasbani G , TaherAT , JawadAet al.COVID-19, antiphospholipid antibodies, and catastrophic antiphospholipid syndrome: a possible association?Clin. Med. Insights Arthritis Musculoskelet. Disord.13, 1179544120978667 (2020).
   Web of Science ®Google Scholar
• KawasakiT , KawaiT. Toll-like receptor signaling pathways. 5, 1–8 (2014).
   Google Scholar
• ZhangS , LiuY , WangXet al.SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. 7, 1–22 (2020).
   Google Scholar
• TungML , TanB , CherianRet al.Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. Rheumatol. Adv. Pract.5, 1–14 (2021).
   Google Scholar
• TangK , HsuB , ChenDet al.Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review. 12 (2021).
   Google Scholar
• OliveiraDC , CorreiaA , OliveiraC. The issue of the antiphospholipid antibody syndrome. J. Clin. Med. Res.12, 286–292 (2020).
   PubMedGoogle Scholar
• HansenESH , MoellerAL , BackerVet al.Severe outcomes of COVID-19 among patients with COPD and asthma. ERJ Open Res.7, 00594–02020 (2021).
   PubMedGoogle Scholar
• ÖztürkAB , ÇağlayanB. Angiotensin converting enzyme-2 (ACE2) receptors, asthma and severe covid-19 infection risk. Eur. Ann. Allergy Clin. Immunol.52, 282–285 (2020).
   PubMed Web of Science ®Google Scholar
• LiuS , ZhiY , YingS. COVID-19 and Asthma: Reflection During the Pandemic. Clin. Rev. Allergy Immunol.59, 78–88 (2020).
   PubMed Web of Science ®Google Scholar
• BouazzaB , Hadj-SaidD , PescatoreKAet al.Are patients with asthma and chronic obstructive pulmonary disease preferred targets of COVID-19?Tuberc. Respir. Dis. (Seoul).84, 22–34 (2021).
   PubMed Web of Science ®Google Scholar
• Gaspar-MarquesJ , van ZellerM , Carreiro-MartinsPet al.Severe asthma in the era of COVID-19: a narrative review. Pulmonology28, 34–43 (2021).
   PubMed Web of Science ®Google Scholar
• BrancoACCC , SatoMN , AlbercaRW. The possible dual role of the ACE2 receptor in asthma and coronavirus (SARS-CoV2) infection. Front Cell Infect. Microbiol.10, 1–6 (2020).
   PubMed Web of Science ®Google Scholar
• TseGMK , ToKF , ChanPKSet al.Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J. Clin. Pathol.57, 260–265 (2004).
   PubMed Web of Science ®Google Scholar
• PranataR , SoerotoAY , HuangIet al.Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int. J. Tuberc. Lung Dis.24, 838–843 (2020).
   PubMed Web of Science ®Google Scholar
• Hughes-VisentinA , PaulABM. Asthma and COVID-19: what do we know now. Clin. Med. Insights Circ Respir. Pulm. Med.14 (2020).
   Web of Science ®Google Scholar
• BrosnahanSB , JonkmanAH , KuglerMCet al.Covid-19 and respiratory system disorders current knowledge, future clinical and translational research questions. Arterioscler. Thromb. Vasc. Biol.2586–2597 (2020).
   PubMed Web of Science ®Google Scholar
• ÇakırEdis E. Chronic pulmonary diseases and COVID-19. Turkish Thorac. J.21, 345–349 (2020).
   PubMed Web of Science ®Google Scholar
• CaminatiM , VultaggioA , MatucciAet al.Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity. Respir. Med.176, 106261 (2021).
   PubMed Web of Science ®Google Scholar
• QuagliarielloV , BonelliA , CaronnaAet al.SARS-CoV-2 infection and cardioncology: from cardiometabolic risk factors to outcomes in cancer patients. Cancers (Basel)12, 1–25 (2020).
   Web of Science ®Google Scholar
• DerosaL , MelenotteC , GriscelliFet al.The immuno-oncological challenge of COVID-19. Nat. Cancer1, 946–964 (2020).
   PubMedGoogle Scholar
• YeC , QiL , WangJet al.COVID-19 pandemic: advances in diagnosis, treatment, organoid applications and impacts on cancer patient management. Front Med.8, 5–7 (2021).
   Web of Science ®Google Scholar
• BakounyZ , HawleyJE , ChoueiriTKet al.COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell38, 629–646 (2020).
   PubMed Web of Science ®Google Scholar
• SilvermanDA , LinC , TamakiAet al.Respiratory and pulmonary complications in head and neck cancer patients: evidence-based review for the COVID-19 era. Head Neck42, 1218–1226 (2020).
   PubMed Web of Science ®Google Scholar
• MohantyA , AgnihotriS , MehtaAet al.Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 Resource Centre is Hosted on Elsevier Connect, the Company's Public News and Information.52 (2020).
   Google Scholar
• FlorianSlimanoa , b* , AmandineBaudouincet al.Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 Resource Centre is Hosted on Elsevier Connect, the Company's Public News and Information52 (2020).
   Google Scholar
• ZhangW , GaoY , HuGet al.Lymphocyte may be a reference index of the outcome of cancer patients with COVID-19. Aging (Albany NY)13, 7733–7744 (2021).
   PubMedGoogle Scholar
• ElgoharyS , ElkhodiryAA , AminNSet al.Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients? (2021).
   Google Scholar
• ZhangL , ZhuF , XieLet al.Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 Resource Centre is Hosted on Elsevier Connect, the Company's Public News and Information52 (2020).
   Google Scholar
• RamaniVK , NaikR. A narrative review of the pathophysiology of COVID-19 infection among cancer patients: current evidence and research perspectives. Heal Sci Reports4, 1–10 (2021).
   Google Scholar
• BersanelliM. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy12, 269–273 (2020).
   PubMed Web of Science ®Google Scholar
• ChavdaVP , BezbaruahR , AthalyeMet al.Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena. Viruses14, 759 (2022).
   PubMed Web of Science ®Google Scholar
• ChenR-P , ChavdaVP , PatelABet al.Phytochemical delivery through transferosome (phytosome): an advanced transdermal drug delivery for complementary medicines. Front Pharmacol.13, 850862 (2022).
   PubMed Web of Science ®Google Scholar
• KrishnanA , GangadaranP , ChavdaVPet al.Convalescent serum-derived exosomes: attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery. Exp. Biol. Med. (Maywood), 15353702221092984 (2022).
   Web of Science ®Google Scholar
• ChavdaVP , PatelAB , MistryKJet al.Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges [Internet]. Front. Oncol. (2022
   Web of Science ®Google Scholar
• Al-SamkariH , KarpLeaf RS , DzikWHet al.COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood136, 489–500 (2020).
   PubMed Web of Science ®Google Scholar
• KasinathanG , SatharJ. Haematological manifestations mechanisms of thrombosis and anti-coagulation in COVID-19 disease: a review. Ann. Med. Surg.56, 173–177 (2020).
   PubMed Web of Science ®Google Scholar
• MerrillJT , ErkanD , WinakurJet al.Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat. Rev. Rheumatol.16, 581–589 (2020).
   PubMed Web of Science ®Google Scholar
• ChanNC , WeitzJI. COVID-19 coagulopathy, thrombosis, and bleeding. Blood136, 381–383 (2020).
   PubMed Web of Science ®Google Scholar
• MadjunkovM , DviriM , LibrachC. A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: a Canadian perspective. J. Ovarian. Res.13, 1–18 (2020).
   Web of Science ®Google Scholar
• AlloteyJ , StallingsE , BonetMet al.Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ370, m3320 (2020).
   PubMed Web of Science ®Google Scholar
• ArdestaniZadeh A , ArabD. COVID-19 and male reproductive system: pathogenic features and possible mechanisms. J. Mol. Histol., 1–10 (2021).
   Web of Science ®Google Scholar
• MartiniAE. COVID-19 in pregnancy. 2, 2200 (2020).
   Google Scholar
• MahaseE. Covid-19: pregnant women with virus are more likely to need intensive care, study finds. BMJ370, m3391 (2020).
   PubMedGoogle Scholar
• ChouSHY , BeghiE , HelbokRet al.Global incidence of neurological manifestations among patients hospitalized with COVID-19 – a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open4, 1–14 (2021).
   Web of Science ®Google Scholar
• KhatoonF , PrasadK , KumarV. Neurological manifestations of COVID-19: available evidences and a new paradigm. J. Neurovirol.26, 619–630 (2020).
   PubMed Web of Science ®Google Scholar
• PezziniA , PadovaniA. Lifting the mask on neurological manifestations of COVID-19. Nat. Rev. Neurol.16, 636–644 (2020).
   PubMed Web of Science ®Google Scholar
• SlykS , DomitrzI. Neurological manifestations of SARS-CoV-2 – a systematic review. Neurol. Neurochir. Pol.54, 378–383 (2020).
   PubMed Web of Science ®Google Scholar
• de SezeJ. The neurological manifestations of COVID-19. Prat. Neurol. – FMC11, 145–146 (2020).
   Google Scholar
• TsivgoulisG , PalaiodimouL , KatsanosAHet al.Neurological manifestations and implications of COVID-19 pandemic. Ther. Adv. Neurol. Disord.13, 1–14 (2020).
   Web of Science ®Google Scholar
• SteardoL , SteardoL , VerkhratskyA. Psychiatric face of COVID-19. Transl. Psychiatry10 (2020).
   PubMed Web of Science ®Google Scholar
• ConversationFT. India is struggling against a rapid increase in Covid-19 cases, but a nasty and rare fungal infection affecting some coronavirus patients is dealing the country a double blow. 1–9 (2021).
   Google Scholar
• DoTP , RemmersA , SchytzHWet al.Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology92, 134–144 (2019).
   PubMed Web of Science ®Google Scholar
• HuangC , HuangL , WangYet al.6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England)397, 220–232 (2021).
   PubMed Web of Science ®Google Scholar
• DebP , MollaMMA , Saif-Ur-RahmanKM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosaf. Heal.3, 87–91 (2021).
   PubMedGoogle Scholar
• RuggeriRM , CampennìA , SiracusaMet al.Subacute thyroiditis in a patient infected with SARS-COV-2: an endocrine complication linked to the COVID-19 pandemic. Hormones (Athens)20, 219–221 (2021).
   PubMedGoogle Scholar